Immix Posts Q3 Loss, $340.9M Cash Into Mid-2028, Adds Two Commercial Leads
IMMX has more than doubled off its 52-week low of $3.26.
Summary
Immix reported a $13.9 million third-quarter net loss and $340.9 million in cash and marketable securities, which management expects to fund operations into mid-2028. It also named two senior commercial/regulatory leaders and set an ASH oral presentation of NEXICART-2 interim data for December 14, 2026.
Key Events · Earnings and Guidance · IMMX
-
Q3 Loss of $13.9M on $15.9M Spend
Third-quarter operating expenses were $15.9 million, of which $5.5 million R&D and $10.4 million G&A, producing a $13.9 million net loss.
-
Cash of $340.9M Funds Into Mid-2028
Cash, cash equivalents and marketable securities reached $340.9 million at September 30, 2026, up from $234.1 million at June 30, and management expects runway into mid-2028.
-
Two Senior Commercial-Stage Hires
David He, MD, PhD joined as SVP, Head of Technical Operations, and Karin McIntosh as SVP, Head of Regulatory Affairs, alongside additional commercial, regulatory, quality and medical affairs staff.
-
ASH Oral Presentation December 14, 2026
Interim NEXICART-2 clinical data will be presented orally at the 68th ASH Annual Meeting in New Orleans on December 14, 2026; the company also presents at the J.P. Morgan Healthcare Conference January 11-14, 2027.
Analysis · IMMX · Life Sciences
The quarter itself is unremarkable — $15.9 million of operating spend and a $13.9 million net loss — but the balance sheet is the story: $340.9 million in cash and marketable securities at September 30 is expected to fund operations into mid-2028, comfortably past the planned mid-2027 BLA submission and the first-half 2027 NEXICART-3 front-line trial start. That removes any near-term financing need, which matters because the company already raised $125 million at $11.00 per share in September. The two senior hires — a head of technical operations who worked on two approved BCMA CAR-Ts and a regulatory head with multiple FDA approvals — are the concrete steps behind the commercial launch preparation. The next hard data point is the interim NEXICART-2 oral presentation at ASH on December 14, 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMX was trading at $8.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $669M. The 52-week trading range was $3.26 to $15.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.